 |
|
|
| |
Eight Weeks of Glecaprevir/Pibrentasvir is Well Tolerated and Yields High Sustained Virological Response in HCV-Infected Treatment-Naïve Patients With Compensated Cirrhosis: Final Results From the CREST Study
|
| |
| |
EASL 2022 June 22-26 London
M. Cornberg1, A. Abergel2, A. Aghemo3, A. Ahumada4, M. Andreoni5, T. Asselah6, A. Bhagat7, M. Bondin7, I. Butrymowicz7, M. Carmiel8, G. Chodick9,10, B. Conway11, A. Gasbarrini12, D. Hüppe13, F. Jorquera Plaza14, P. Lampertico15,16, M.L. Manzano Alonso17, L. Myles18, M. Persico19, A. Ramji20, C. Sarrazin21,
D. Semizarov7, Y. Song7, S. Sonparote7, E. Villa22, C. Weil9, J.I. Uriz Otano23,24 and The CREST Study Group
|
| |
|
|
|
|
|
